
TSE:ATS
This summary was created by AI, based on 4 opinions in the last 12 months.
ATS Automation Tooling Systems (ATS-T) shows a mixed yet optimistic outlook from various analysts, with reviews highlighting the company’s strong position within the automation sector. Although the latest quarter experienced increased revenues, bookings have softened slightly, leading to missed earnings due to a different mix and timing rather than a drop in demand. Analysts continue to recognize the company's focus on higher-quality business, sacrificing short-term growth for longer-term gains. There remains a strong pipeline of projects, and industry structural changes, such as reshoring and labor scarcity, are positioning ATS well for future success. With price targets around $49 to $50, the prevailing sentiment indicates a promising upside potential from current levels, despite some recent volatility.
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. It is sensitive to broad economic growth and is likely why the shares are dragging down. Trading at 16x forward earnings and good growth is expected. Risks are most likely already priced in. Cost pressures and slowdowns are possible, but many companies, including ATA will manage through them. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The stock is up more than 100% in the past year. It has slightly declined but it is more on sell on news right now. EPS estimates beat last quarter. Backlog is nearly $1.5B and sales are climbing 48%. A solid quarter. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Could deliver good growth although it is more in the cyclical business. Business is solid and the stock has hit more investor’s radar. 3 year + timeframe. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Earnings report was overall good. Revenues beat expectations by $20M. Backlog is up 23% to $1.1B and EPS is $0.34. EBITDA margins have increased. Their acquisition of BioDot is going well. Shares are up 4% after the report. Unlock Premium - Try 5i Free